Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
复制标题
DOI：
10.1086/590566
复制
发表时间：
2008-09-01
期刊：
影响因子：
--
通讯作者：
De Pauw BE
中科院分区：
文献类型：
--
作者：
Segal BH;Herbrecht R;Stevens DA;Ostrosky-Zeichner L;Sobel J;Viscoli C;Walsh TJ;Maertens J;Patterson TF;Perfect JR;Dupont B;Wingard JR;Calandra T;Kauffman CA;Graybill JR;Baden LR;Pappas PG;Bennett JE;Kontoyiannis DP;Cordonnier C;Viviani MA;Bille J;Almyroudis NG;Wheat LJ;Graninger W;Bow EJ;Holland SM;Kullberg BJ;Dismukes WE;De Pauw BE
侵袭性真菌病(IFDS)已成为免疫功能高度低下患者发病和死亡的主要原因。诊断IFD的权威共识标准在建立抗真菌试验的资格标准方面是有用的。重要的是需要对IFD的结果形成共识定义，以形成临床试验中评估治疗成败的标准。因此，召集了一个由霉菌研究小组和欧洲癌症研究和治疗组织组成的国际专家小组，为评估IFDS临床试验的治疗反应和确定研究结果提出指导方针。讨论的主要真菌疾病包括念珠菌属、曲霉菌属和其他霉菌引起的侵袭性疾病、新生隐球菌属、被膜组织胞浆菌和免疫球虫。我们还讨论了评估结果的潜在陷阱，例如相互冲突的临床、放射学和/或真菌学数据以及知识上的差距。
Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.
登录
查看更多内容
影响因子：
11.8
作者：
Ascioglu, S;Rex, JH;Walsh, TJ
通讯作者：
Walsh, TJ
影响因子：
11.8
作者：
Bennett, JE;Powers, J;Verweij, P
通讯作者：
Verweij, P
影响因子：
168.9
作者：
Brouwer, AE;Rajanuwong, A;Harrison, TS
通讯作者：
Harrison, TS
影响因子：
5.9
作者：
GALGIANI, JN;STEVENS, DA;CLOUD, GA
通讯作者：
CLOUD, GA
影响因子：
11.8
作者：
Goldman, M;Zackin, R;Aberg, JA
通讯作者：
Aberg, JA